Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
SOUTH SAN FRANCISCO, Calif., March 08, 2017 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 29th Annual ROTH Conference taking place from March 12-15, 2017 in Dana Point, California.
Mateon’s management will present a company overview on Wednesday, March 15, 2017 at 7:30 am pacific time. A live webcast of the presentation will be available on the company’s website at www.mateon.com in “Events & Presentations” under the “Investors & News” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACTS Investors: PCG Advisory Group Stephanie Prince, Managing Director [email protected] 646-762-4518 Media: JPA Health Communications Nic DiBella [email protected] 617-945-5183
